Cost-utility of point-of-care viscoelastic hemostatic assays in the management of bleeding during cardiac surgery: A single-blinded prospective multicenter stepped wedge cluster randomized trial in French context - 28/02/26
, Elodie Boissier c, 1, Karim Lakhal a, 1, Sandrine Grosjean d, François Labaste e, Emmanuel Robin f, Adrien Bougle g, Mathieu Mattei h, Jérôme Morel i, Véronique Wurtz j, Paul-Michel Mertes k, Diane Zlotnik l, David Lagier m, Antoine Beurton n, Emmanuel Rineau o, Marc-Olivier Fischer p, Marc-Antoine May q, Anne Médard r, Guillaume Guimbretiere s, Isabelle Durand-Zaleski t, Morgane Pere u, Bertrand Rozec a, v, 2, Jean-Christophe Rigal a, 2Abstract |
Background |
The IMOTEC study aims to determine whether a point-of-care viscoelastic hemostatic assay (VHA)-guided algorithm is cost-effective for the management of ongoing bleeding.
Methods |
Stepped wedge cluster randomized trial, patient blinded, conducted at 16 French academic cardiac surgery centers from 01/2017 to 02/2020. Adults undergoing elective or urgent cardiac surgery with ongoing bleeding were enrolled during 2 successive inclusion periods: 1) transfusion guided on standard hemostasis tests (control period), and 2) transfusion using a VHA-guided algorithm. The primary objective was to estimate the efficiency of VHA based on the 1-year incremental cost-utility ratio (ICUR, primary outcome). Secondary outcomes included transfusion, postoperative complications, duration of stay in-hospital, reintervention, and mortality.
Results |
1095 patients were randomized, and 1044 (95.3%) were analyzed. The mean utility was 0.60 (±0.30) in the VHA vs. 0.61 (±0.30) in the control period, adjusted difference, −0.01 [95% CI, −0.09 to 0.07]. The ICUR did not suggest that the VHA-guided algorithm was cost-effective. One-year mortality was 12.0% for VHA and 10.9% for control, Hazard Ratio, 1.69 [95% CI, 0.98–2.89], P = .06. The frequency of plasma and platelet transfusions was significantly lower in the VHA compared to the control period (respectively, 48.8% vs. 72.4%, P < 0.0001 and 52.3% vs. 74.1%, P = .0002), whereas fibrinogen administration was more frequent in the VHA period (58.4% vs. 47.0%, P = .002). The median in-hospital length of stay was significantly shorter in the VHA vs . control period: 11.0 days (8.0–18.0) vs. 14.0 (9.0–22.0), P = .02.
Conclusions |
The ICUR did not suggest that VHA was cost-effective in cardiac surgery patients with ongoing bleeding, compared with standard tests.
Trial registration |
Clinical trial submission: November 2, 2016
Registry name: Cost-Utility Analysis of Management of Peri Operative Hemorrhage Following Cardiac Surgery With Cardiopulmonary Bypass (IMOTEC)
ClinicalTrials.gov Identifier: NCT02972684
URL registry: NCT02972684
Le texte complet de cet article est disponible en PDF.Keywords : Cardiac surgery, Transfusion-saving strategy, Viscoelastic hemostatic assays, Severe hemorrhage, Patient blood management, Ongoing bleeding
Plan
Vol 45 - N° 3
Article 101704- mai 2026 Retour au numéro
Article précédent
- The analgesic effects of ultrasound-guided recto-intercostal fascial plane block in laparoscopic hiatus hernia repair: A randomized double-blind controlled study
- Osama Mohammed Rehab, Doha Mohammed Bakr, Dina Ahmed El Malla, Rehab Abd El Fattah Helal, Islam Morsy, Marwa Eloraby
- Mortality associated with the perioperative management of patients with proximal femur fractures: A machine learning prediction model
- Thibaud Rocco, François Antonini, Thibaut Florant, Bernard Lassale, Arthur Malet, Olivier Sanzeri, Stéphanie Durieux, Alisée Delbrel, Lucia Natale, Benjamin Blondel, Solène Prost, Romain Ambrosino, Damien Lami, Christophe Jacquet, Bruno Pastène, Carole Bechis, Marion Poirier, Laura Kubacsi, Xavier Flecher, Marie Le Baron, Sylvain Takerkart, Geoffray Agard, Lionel Velly, Marc Leone, Pierre Simeone
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?